325 related articles for article (PubMed ID: 16313796)
1. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
4. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.
Canto MI; Goggins M; Hruban RH; Petersen GM; Giardiello FM; Yeo C; Fishman EK; Brune K; Axilbund J; Griffin C; Ali S; Richman J; Jagannath S; Kantsevoy SV; Kalloo AN
Clin Gastroenterol Hepatol; 2006 Jun; 4(6):766-81; quiz 665. PubMed ID: 16682259
[TBL] [Abstract][Full Text] [Related]
5. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
6. Modern imaging methods versus clinical assessment in the evaluation of hospital in-patients with suspected pancreatic disease.
Rösch T; Schusdziarra V; Born P; Bautz W; Baumgartner M; Ulm K; Lorenz R; Allescher HD; Gerhardt P; Siewert JR; Classen M
Am J Gastroenterol; 2000 Sep; 95(9):2261-70. PubMed ID: 11007227
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies.
Amoura Z; Duhaut P; Huong DL; Wechsler B; Costedoat-Chalumeau N; Francès C; Cacoub P; Papo T; Cormont S; Touitou Y; Grenier P; Valeyre D; Piette JC
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1279-82. PubMed ID: 15894686
[TBL] [Abstract][Full Text] [Related]
8. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
9. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
10. Improved early diagnosis of cystadenocarcinoma of the pancreas.
Wu H; Cheng NS; Zhang YG; Luo HZ; Yan LN; Li J
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):87-91. PubMed ID: 17287173
[TBL] [Abstract][Full Text] [Related]
11. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis of pancreatic cancer.
Brand R
Cancer J; 2001; 7(4):287-97. PubMed ID: 11561605
[TBL] [Abstract][Full Text] [Related]
13. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
Zhang Y; Ji SR; Feng DX; Ji J; Han TQ
Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190
[TBL] [Abstract][Full Text] [Related]
14. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
15. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma].
Pei DP
Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060
[TBL] [Abstract][Full Text] [Related]
16. [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer].
Dai MH; Zhao YP; Cai LX; Zhu Y
Zhonghua Wai Ke Za Zhi; 2003 May; 41(5):332-5. PubMed ID: 12892584
[TBL] [Abstract][Full Text] [Related]
17. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer.
Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH
Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340
[TBL] [Abstract][Full Text] [Related]
20. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
